Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $43.80

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $43.80.

COLL has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Piper Sandler restated a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Friday, January 10th.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors have recently modified their holdings of the stock. Pacer Advisors Inc. lifted its stake in shares of Collegium Pharmaceutical by 31.8% in the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after buying an additional 821,541 shares in the last quarter. Rubric Capital Management LP lifted its stake in shares of Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after buying an additional 499,473 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Collegium Pharmaceutical by 43.6% in the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after buying an additional 215,874 shares in the last quarter. Emerald Advisers LLC raised its stake in Collegium Pharmaceutical by 27.2% during the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after purchasing an additional 177,129 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after purchasing an additional 175,892 shares during the period.

Collegium Pharmaceutical Stock Down 0.7 %

NASDAQ:COLL opened at $32.96 on Monday. The firm has a market capitalization of $1.06 billion, a P/E ratio of 14.21 and a beta of 0.80. Collegium Pharmaceutical has a 1-year low of $28.39 and a 1-year high of $42.29. The company’s fifty day moving average price is $30.54 and its 200-day moving average price is $34.09. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.